Since the isolation of SARS-CoV-2 and the study of its infection mechanisms, scientists have been trying to understand how this virus accesses the brain and produces neurological symptoms.
After political leaders across the globe made patents and other intellectual property (IP) safeguards the scapegoat for disparities in access to COVID-19 vaccines, the biopharma industry is sharing its vision for how to deal with the foundational issues of equitable access in pandemics to come – and it has nothing to do with IP waivers like the one World Trade Organization members adopted last month.
Illumina Inc.’s acquisition of Grail Inc., of Menlo Park, Calif., may or may not prove to be a case of jumping the regulatory gun, but the move to date has not racked up significant financial penalties for the company. That may soon change per a statement by the European Commission, which said that Illumina may find itself on the receiving end of “hefty fines,” a statement made by EC executive vice president Margrethe Vestager.
Oxford Science Enterprises, an independent investor specializing in building companies through its relationship with the U.K.’s University of Oxford, has raised a further £250 million (US$300 million) to translate academic research into commercial products and businesses.
A new assay developed by Metadeq Inc. may be bringing the days of the invasive liver biopsy for non-malignant conditions to a close. The company’s liquid biopsy successfully used the presence of two proteins in blood to identify and stage non-alcoholic steatohepatitis (NASH) and liver fibrosis in a study published in Gut.
Illumina Inc., of San Diego, is struggling to complete the regulatory side of its acquisition of Grail Inc., of Menlo Park, Calif., thanks in part to the U.S. Federal Trade Commission’s (FTCs) ongoing review of the transaction. However, Illumina is also facing stiff winds in Europe where the General Court of the European Union rejected the company’s bid to push the deal through despite the opposition of the European Commission (EC).
Amid the ongoing war Russia is waging in Ukraine, representatives of several Western biopharma and medical device companies met with Russian health officials this week to discuss an uninterrupted drug supply, maintenance of medical equipment in Russia and software updates. Russian Minister of Health Mikhail Murashko told the group his agency’s top priority is an uninterrupted drug supply. He recognized that dialogue between the government and manufacturers is necessary to maintain that supply.
Sonio SAS raised just over $5 million in its seed round to develop artificial intelligence (AI) software allowing health care professionals to determine the most appropriate pregnancy care. Its Sonio Diagnostic software delivers decision support for fetal ultrasound used in antenatal diagnostics.
The Royal Academy of Engineering in the U.K. is supporting another batch of health care innovations in developing countries, which range from surgical robots to tissue regeneration material. A number of entrepreneurs supported by the Academy’s Leaders in Innovation Fellowships (LIF) Global 2022 program were recently given the additional opportunity to secure further expert mentoring from engineers from the Academy's network and join a peer network of U.K. founders.
Kranus Health GmbH has raised $6.5 million in series A funding to ramp commercialization of its digital therapy for treating erectile dysfunction (ED). Eleven European investors participated in this fundraising. The round was led by early-stage health care venture capitalists Karista SAS, while Peak Pride Management GmbH also joined the funding round.
RSS
